336 related articles for article (PubMed ID: 2532558)
1. D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour.
Robertson HA; Peterson MR; Murphy K; Robertson GS
Brain Res; 1989 Dec; 503(2):346-9. PubMed ID: 2532558
[TBL] [Abstract][Full Text] [Related]
2. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
Pollack AE; Yates TM
Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
[TBL] [Abstract][Full Text] [Related]
3. Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos.
Robertson GS; Vincent SR; Fibiger HC
Brain Res; 1990 Jul; 523(2):288-90. PubMed ID: 2144781
[TBL] [Abstract][Full Text] [Related]
4. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Paul ML; Graybiel AM; David JC; Robertson HA
J Neurosci; 1992 Oct; 12(10):3729-42. PubMed ID: 1357113
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic grafts in the striatum reduce D1 but not D2 receptor-mediated rotation in 6-OHDA-lesioned rats.
Robertson GS; Fine A; Robertson HA
Brain Res; 1991 Jan; 539(2):304-11. PubMed ID: 1675908
[TBL] [Abstract][Full Text] [Related]
6. Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity.
Paul ML; Currie RW; Robertson HA
Neuroscience; 1995 May; 66(2):347-59. PubMed ID: 7477877
[TBL] [Abstract][Full Text] [Related]
7. Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal dynorphin expression in the 6-hydroxydopamine lesioned rat.
Bronstein DM; Ye H; Pennypacker KR; Hudson PM; Hong JS
Brain Res Mol Brain Res; 1994 May; 23(3):191-203. PubMed ID: 7914658
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats.
Pollack AE; Fink JS
Brain Res; 1996 Dec; 743(1-2):124-30. PubMed ID: 9017239
[TBL] [Abstract][Full Text] [Related]
10. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
11. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Doucet JP; Nakabeppu Y; Bedard PJ; Hope BT; Nestler EJ; Jasmin BJ; Chen JS; Iadarola MJ; St-Jean M; Wigle N; Blanchet P; Grondin R; Robertson GS
Eur J Neurosci; 1996 Feb; 8(2):365-81. PubMed ID: 8714707
[TBL] [Abstract][Full Text] [Related]
12. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
13. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
Fletcher GH; Starr MS
Neuroscience; 1987 Dec; 23(3):1001-10. PubMed ID: 2963970
[TBL] [Abstract][Full Text] [Related]
14. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
15. D1 priming enhances both D1- and D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats.
Pollack AE; Thomas LI
Pharmacol Biochem Behav; 2010 Jan; 94(3):346-51. PubMed ID: 19800912
[TBL] [Abstract][Full Text] [Related]
16. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
Wirtshafter D; Osborn CV
Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
[TBL] [Abstract][Full Text] [Related]
17. Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression.
Labandeira-Garcia JL; Rozas G; Lopez-Martin E; Liste I; Guerra MJ
Exp Brain Res; 1996 Feb; 108(1):69-84. PubMed ID: 8721156
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6-hydroxydopamine-lesioned rats.
Pollack AE; Turgeon SM; Fink JS
Neuroscience; 1997 Jul; 79(1):79-93. PubMed ID: 9178866
[TBL] [Abstract][Full Text] [Related]
19. The effects of dopamine D-1 and D-2 receptor subtype agonists on nigrostriatal opioid dynorphin and enkephalin immunostaining in 6-hydroxydopamine lesioned rats.
Jiang HK; Wang JY
Chin J Physiol; 1991; 34(4):413-25. PubMed ID: 1687937
[TBL] [Abstract][Full Text] [Related]
20. Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats: an autoradiographic study.
Savasta M; Mennicken F; Chritin M; Abrous DN; Feuerstein C; Le Moal M; Herman JP
Neuroscience; 1992; 46(3):729-38. PubMed ID: 1532053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
